PARP-Inhibitor nun in Erstlinie bei pMMR-Endometriumkarzinom einsetzbar

Im Focus Onkologie 2026

View at publisher

Authors: Claudia Schöllmann

DOI: 10.1007/s15015-025-4472-y

Cited by: 0

Fields of Study & Subjects

PARP inhibition in cancer therapy Endometrial and Cervical Cancer Treatments Advanced Breast Cancer Therapies